The latest price target for Altimmune (NASDAQ:ALT) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $12.00 expecting ALT to rise to within 12 months (a possible 42.77% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Altimmune (NASDAQ:ALT) was provided by HC Wainwright & Co., and Altimmune reiterated their buy rating.

There is no last upgrade for Altimmune

The last downgrade for Altimmune Inc happened on April 29, 2024 when Guggenheim changed their price target from N/A to N/A for Altimmune Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Altimmune (ALT) rating was a reiterated with a price target of $12.00 to $12.00. The current price Altimmune (ALT) is trading at is $8.40, which is out of the analyst’s predicted range.